Department of Urology, Sir Charles Gairdner Hospital, Perth, Australia.
Department of Urology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA, 6009, Australia.
Ir J Med Sci. 2024 Aug;193(4):1729-1734. doi: 10.1007/s11845-024-03637-1. Epub 2024 Mar 28.
Multiparametric MRI and the transperineal approach have become standard in the diagnostic pathway for suspected prostate cancer. Targeting of MRI lesions is performed at most centers, but the routine use of systematic cores is controversial. We aim to assess the value of obtaining systematic cores in patients undergoing cognitive fusion targeted double-freehand transperineal prostate biopsy.
Patients who underwent a cognitive fusion, freehand TPB at a single tertiary urology service (Perth, Australia) between November 2020 and November 2021 were retrospectively reviewed. Patients were included if they were biopsy naive and had a clinical suspicion of prostate cancer, based on their mpMRI results. Both targeted and systematic cores were taken at the time of their biopsy.
One hundred forty patients suited the selection criteria. Clinically significant cancer was identified in 63% of patients. Of those that had clinically significant cancer, the target lesion identified 91% of the disease, missing 9% of patients whom the target biopsy detected non-clinically significant cancer but was identified in the systematic cores. Higher PI-RADS category patients were also found to be associated with an increasing likelihood of identifying clinically significant cancer within the target.
In patients with PI-RADS 3 and higher, the target biopsy can miss up to 9% of clinically significant cancer. Systematic cores can add value as they can also change management by identifying a high-risk disease where only intermediate cancer was identified in the target. A combination of targeted and systematic cores is still required to detect cancer.
多参数 MRI 和经会阴入路已成为疑似前列腺癌诊断途径的标准。大多数中心都对 MRI 病变进行靶向定位,但系统核心的常规使用仍存在争议。我们旨在评估在接受认知融合靶向双徒手经会阴前列腺活检的患者中获取系统核心的价值。
回顾性分析了 2020 年 11 月至 2021 年 11 月在澳大利亚珀斯的一家三级泌尿科服务机构接受认知融合、徒手 TPB 的患者。如果患者具有前列腺癌的临床可疑症状(基于他们的 mpMRI 结果)且为初次活检,则纳入研究。在活检时,同时进行靶向和系统核心活检。
140 名患者符合选择标准。63%的患者发现了临床显著的癌症。在患有临床显著癌症的患者中,目标病变识别了 91%的疾病,而目标活检漏诊了 9%的患者,这些患者的目标活检检测到非临床显著癌症,但在系统核心中被发现。PI-RADS 评分较高的患者也更有可能在目标中发现临床显著癌症。
在 PI-RADS 3 及以上的患者中,目标活检可能会漏诊多达 9%的临床显著癌症。系统核心可以增加价值,因为它们还可以通过识别目标中仅发现中度癌症但实际上是高危疾病的患者来改变管理。仍然需要靶向和系统核心的组合来检测癌症。